A Real-World Perspective on Molecular Design

Journal of Medicinal Chemistry

Volumn 59, Issue 9, 2016, Pages 4087-4102

  Kuhn, Bernd ^a   Guba, Wolfgang ^a   Hert, Jérôme ^a   Banner, David ^a   Bissantz, Caterina ^a   Ceccarelli, Simona ^a   Haap, Wolfgang ^a   Körner, Matthias ^a   Kuglstatter, Andreas ^a   Lerner, Christian ^a   Mattei, Patrizio ^a   Neidhart, Werner ^a   Pinard, Emmanuel ^a   Rudolph, Markus G ^a   Schulz Gasch, Tanja ^a   Woltering, Thomas ^a   Stahl, Martin ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CATHEPSIN L; CATHEPSIN S; CATHEPSIN S INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESTERASE INHIBITOR; FATTY ACID BINDING PROTEIN 4; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; HORMONE SENSITIVE LIPASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE INHIBITOR; SOMATOSTATIN RECEPTOR 5; TRYPTASE; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; IC50; LIPOPHILICITY; MOLECULAR RECOGNITION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; CONFORMATION; MOLECULAR LIBRARY;

DRUG DESIGN; MOLECULAR CONFORMATION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84969579958     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01875     Document Type: Article

References (75)

1. Stahl, M.; Guba, W.; Kansy, M. Integrating Molecular Design Resources within Modern Drug Discovery Research: The Roche Experience Drug Discovery Today 2006, 11 (7-8) 326-333 10.1016/j.drudis.2006.02.008
2. Feng, J. A.; Aliagas, I.; Bergeron, P.; Blaney, J. M.; Bradley, E. K.; Koehler, M. F. T.; Lee, M.-L.; Ortwine, D. F.; Tsui, V.; Wu, J.; Gobbi, A. An Integrated Suite of Modeling Tools That Empower Scientists in Structure- and Property-Based Drug Design J. Comput.-Aided Mol. Des. 2015, 29 (6) 511-523 10.1007/s10822-015-9845-4
3. Hillisch, A.; Heinrich, N.; Wild, H. Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence ChemMedChem 2015, 10 (12) 1958-1962 10.1002/cmdc.201500346
4. Loughney, D.; Claus, B. L.; Johnson, S. R. To Measure Is to Know: An Approach to CADD Performance Metrics Drug Discovery Today 2011, 16 (13-14) 548-554 10.1016/j.drudis.2011.05.003
5. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M. Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis J. Chem. Inf. Model. 2008, 48 (1) 1-24 10.1021/ci7002494
6. Bissantz, C.; Kuhn, B.; Stahl, M. A Medicinal Chemists Guide to Molecular Interactions J. Med. Chem. 2010, 53 (14) 5061-5084 10.1021/jm100112j
7. Persch, E.; Dumele, O.; Diederich, F. Molecular Recognition in Chemical and Biological Systems Angew. Chem., Int. Ed. 2015, 54 (11) 3290-3327 10.1002/anie.201408487
8. Ahrén, B. Emerging Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Diabetes Expert Opin. Emerging Drugs 2008, 13 (4) 593-607 10.1517/14728210802584126
9. Gwaltney, S., II. Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase IV Curr. Top. Med. Chem. 2008, 8 (17) 1545-1552 10.2174/156802608786413519
10. Peters, J.-U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.; Boehringer, M.; Hennig, M.; Kuhn, B.; Loeffler, B.-M. Aminomethylpyrimidines as Novel DPP-IV Inhibitors: A 105-Fold Activity Increase by Optimization of Aromatic Substituents Bioorg. Med. Chem. Lett. 2004, 14 (6) 1491-1493 10.1016/j.bmcl.2004.01.019
11. Mattei, P.; Boehringer, M.; Di Giorgio, P.; Fischer, H.; Hennig, M.; Huwyler, J.; Koçer, B.; Kuhn, B.; Loeffler, B. M.; MacDonald, A.; Narquizian, R.; Rauber, E.; Sebokova, E.; Sprecher, U. Discovery of Carmegliptin: A Potent and Long-Acting Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Bioorg. Med. Chem. Lett. 2010, 20 (3) 1109-1113 10.1016/j.bmcl.2009.12.024
12. Stahl, M.; Böhm, H.-J. Development of Filter Functions for Protein-ligand Docking J. Mol. Graphics Modell. 1998, 16 (3) 121-132 10.1016/S1093-3263(98)00018-7
13. Banner, D. W. Principles of Enzyme-Inhibitor Design. In Methods and Principles in Medicinal Chemistry; Böhm, H.-J.; Schneider, G., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2005; pp 163-185, DOI: 10.1002/3527601813.ch7.
14. Boehringer, M.; Fischer, H.; Hennig, M.; Hunziker, D.; Huwyler, J.; Kuhn, B.; Loeffler, B. M.; Luebbers, T.; Mattei, P.; Narquizian, R.; Sebokova, E.; Sprecher, U.; Wessel, H. P. Aryl- and Heteroaryl-Substituted Aminobenzo[a]quinolizines as Dipeptidyl Peptidase IV Inhibitors Bioorg. Med. Chem. Lett. 2010, 20 (3) 1106-1108 10.1016/j.bmcl.2009.12.025
15. Chmurzyńska, A. The Multigene Family of Fatty Acid-Binding Proteins (FABPs): Function, Structure and Polymorphism J. Appl. Genet. 2006, 47 (1) 39-48 10.1007/BF03194597
16. Furuhashi, M.; Hotamisligil, G. S. Fatty Acid-Binding Proteins: Role in Metabolic Diseases and Potential as Drug Targets Nat. Rev. Drug Discovery 2008, 7 (6) 489-503 10.1038/nrd2589
17. Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J.-P.; DArcy, A.; Dorn, A.; Fischli, W.; Grüninger, F.; Güller, R.; Hirth, G.; Märki, H.; Mathews, S.; Müller, M.; Ridley, R.; Stadier, H.; Vieira, E.; Wilhelm, M.; Winkler, F.; Wostl, W. Renin Inhibition by Substituted Piperidines: A Novel Paradigm for the Inhibition of Monomeric Aspartic Proteinases? Chem. Biol. 1999, 6 (3) 127-131 10.1016/S1074-5521(99)89004-8
18. Carcache, D. A.; Hörtner, S. R.; Bertogg, A.; Binkert, C.; Bur, D.; Märki, H. P.; Dorn, A.; Diederich, F. De Novo Design, Synthesis, and In Vitro Evaluation of a New Class of Nonpeptidic Inhibitors of the Malarial Enzyme Plasmepsin II ChemBioChem 2002, 3 (11) 1137-1141 10.1002/1439-7633(20021104)3:11<1137::AID-CBIC1137>3.0.CO;2-A
19. Hilpert, H.; Mauser, H.; Humm, R.; Anselm, L.; Kuehne, H.; Hartmann, G.; Gruener, S.; Banner, D. W.; Benz, J.; Gsell, B.; Kuglstatter, A.; Stihle, M.; Thoma, R.; Sanchez, R. A.; Iding, H.; Wirz, B.; Haap, W. Identification of Potent and Selective Cathepsin S Inhibitors Containing Different Central Cyclic Scaffolds J. Med. Chem. 2013, 56 (23) 9789-9801 10.1021/jm401528k
20. Molecular Operating Environment (MOE); Chemical Computing Group Inc. (1010 Sherbooke St. West, Suite 910, Montreal, QC, H3A 2R7, Canada).
21. Hardegger, L. A.; Kuhn, B.; Spinnler, B.; Anselm, L.; Ecabert, R.; Stihle, M.; Gsell, B.; Thoma, R.; Diez, J.; Benz, J.; Plancher, J.-M.; Hartmann, G.; Banner, D. W.; Haap, W.; Diederich, F. Systematic Investigation of Halogen Bonding in Protein-Ligand Interactions Angew. Chem., Int. Ed. 2011, 50 (1) 314-318 10.1002/anie.201006781
22. Yu, T.; Tagat, J. R.; Kerekes, A. D.; Doll, R. J.; Zhang, Y.; Xiao, Y.; Esposite, S.; Belanger, D. B.; Curran, P. J.; Mandal, A. K.; Siddiqui, M. A.; Shih, N.-Y.; Basso, A. D.; Liu, M.; Gray, K.; Tevar, S.; Jones, J.; Lee, S.; Liang, L.; Ponery, S.; Smith, E. B.; Hruza, A.; Voigt, J.; Ramanathan, L.; Prosise, W.; Hu, M. Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2- a ]-Pyrazine Core ACS Med. Chem. Lett. 2010, 1 (5) 214-218 10.1021/ml100063w
23. Staben, S. T.; Heffron, T. P.; Sutherlin, D. P.; Bhat, S. R.; Castanedo, G. M.; Chuckowree, I. S.; Dotson, J.; Folkes, A. J.; Friedman, L. S.; Lee, L.; Lesnick, J.; Lewis, C.; Murray, J. M.; Nonomiya, J.; Olivero, A. G.; Plise, E.; Pang, J.; Prior, W. W.; Salphati, L.; Rouge, L.; Sampath, D.; Tsui, V.; Wan, N. C.; Wang, S.; Weismann, C.; Wu, P.; Zhu, B.-Y. Structure-Based Optimization of Pyrazolo-Pyrimidine and -Pyridine Inhibitors of PI3-Kinase Bioorg. Med. Chem. Lett. 2010, 20 (20) 6048-6051 10.1016/j.bmcl.2010.08.067
24. Lee, L.-P.; Tidor, B. Optimization of Binding Electrostatics: Charge Complementarity in the Barnase-Barstar Protein Complex Protein Sci. 2001, 10 (2) 362-377 10.1110/ps.40001
25. Sims, P. A.; Wong, C. F.; McCammon, J. A. Charge Optimization of the Interface between Protein Kinases and Their Ligands J. Comput. Chem. 2004, 25 (11) 1416-1429 10.1002/jcc.20067
26. Maass, P.; Schulz-Gasch, T.; Stahl, M.; Rarey, M. ReCore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations J. Chem. Inf. Model. 2007, 47 (2) 390-399 10.1021/ci060094h
27. ReCore in LeadIT; BioSolveIT GmbH: St. Augustin, Germany, 2015.
28. Lauri, G.; Bartlett, P. A. CAVEAT: A Program to Facilitate the Design of Organic Molecules J. Comput.-Aided Mol. Des. 1994, 8 (1) 51-66 10.1007/BF00124349
29. Liang, G.; Aldous, S.; Merriman, G.; Levell, J.; Pribish, J.; Cairns, J.; Chen, X.; Maignan, S.; Mathieu, M.; Tsay, J.; Sides, K.; Rebello, S.; Whitely, B.; Morize, I.; Pauls, H. W. Structure-Based Library Design and the Discovery of a Potent and Selective Mast Cell β-Tryptase Inhibitor as an Oral Therapeutic Agent Bioorg. Med. Chem. Lett. 2012, 22 (2) 1049-1054 10.1016/j.bmcl.2011.11.119
30. Woltering, T. J.; Wostl, W.; Hilpert, H.; Rogers-Evans, M.; Pinard, E.; Mayweg, A.; Göbel, M.; Banner, D. W.; Benz, J.; Travagli, M.; Pollastrini, M.; Marconi, G.; Gabellieri, E.; Guba, W.; Mauser, H.; Andreini, M.; Jacobsen, H.; Power, E.; Narquizian, R. BACE1 Inhibitors: A Head Group Scan on a Series of Amides Bioorg. Med. Chem. Lett. 2013, 23 (14) 4239-4243 10.1016/j.bmcl.2013.05.003
31. Hilpert, H.; Guba, W.; Woltering, T. J.; Wostl, W.; Pinard, E.; Mauser, H.; Mayweg, A. V.; Rogers-Evans, M.; Humm, R.; Krummenacher, D.; Muser, T.; Schnider, C.; Jacobsen, H.; Ozmen, L.; Bergadano, A.; Banner, D. W.; Hochstrasser, R.; Kuglstatter, A.; David-Pierson, P.; Fischer, H.; Polara, A.; Narquizian, R. β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimers Disease J. Med. Chem. 2013, 56 (10) 3980-3995 10.1021/jm400225m
32. Oehlrich, D.; Prokopcova, H.; Gijsen, H. J. M. The Evolution of Amidine-Based Brain Penetrant BACE1 Inhibitors Bioorg. Med. Chem. Lett. 2014, 24 (9) 2033-2045 10.1016/j.bmcl.2014.03.025
33. Shamovsky, I.; Ripa, L.; Börjesson, L.; Mee, C.; Nordén, B.; Hansen, P.; Hasselgren, C.; ODonovan, M.; Sjö, P. Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2 J. Am. Chem. Soc. 2011, 133 (40) 16168-16185 10.1021/ja206427u
34. Pierce, A. C.; Rao, G.; Bemis, G. W. BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease J. Med. Chem. 2004, 47 (11) 2768-2775 10.1021/jm030543u
35. Murray, C. W.; Berdini, V.; Buck, I. M.; Carr, M. E.; Cleasby, A.; Coyle, J. E.; Curry, J. E.; Day, J. E. H.; Day, P. J.; Hearn, K.; Iqbal, A.; Lee, L. Y. W.; Martins, V.; Mortenson, P. N.; Munck, J. M.; Page, L. W.; Patel, S.; Roomans, S.; Smith, K.; Tamanini, E.; Saxty, G. Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors ACS Med. Chem. Lett. 2015, 6 (7) 798-803 10.1021/acsmedchemlett.5b00143
36. Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley, F. D.; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia J. Pharmacol. Exp. Ther. 2008, 325 (2) 681-690 10.1124/jpet.107.132910
37. Stumpfe, D.; Bajorath, J. Exploring Activity Cliffs in Medicinal Chemistry: Miniperspective J. Med. Chem. 2012, 55 (7) 2932-2942 10.1021/jm201706b
38. Proasis, version 3; Desert Scientific Software: Sydney, Australia.
39. Kuhn, B.; Fuchs, J. E.; Reutlinger, M.; Stahl, M.; Taylor, N. R. Rationalizing Tight Ligand Binding through Cooperative Interaction Networks J. Chem. Inf. Model. 2011, 51 (12) 3180-3198 10.1021/ci200319e
40. Groom, C. R.; Allen, F. H. The Cambridge Structural Database in Retrospect and Prospect Angew. Chem., Int. Ed. 2014, 53 (3) 662-671 10.1002/anie.201306438
41. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA, U.S., 1998.
42. Yeaman, S. J. Hormone-Sensitive Lipase-New Roles for an Old Enzyme Biochem. J. 2004, 379 (1) 11-22 10.1042/bj20031811
43. Neidhart, W.; Ackermann, J.; Amrein, K.; Conte, A.; Hunziker, D.; Kuhn, B.; Märki, H. P.; Nettekoven, M.; Ruf, A.; Schulz-Gasch, T.; Mayweg, A. V. Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases Chimia 2015, 69 (7) 407-413 10.2533/chimia.2015.407
44. Pols, T. W. H.; Noriega, L. G.; Nomura, M.; Auwerx, J.; Schoonjans, K. The Bile Acid Membrane Receptor TGR5 as an Emerging Target in Metabolism and Inflammation J. Hepatol. 2011, 54 (6) 1263-1272 10.1016/j.jhep.2010.12.004
45. Martin, R. E.; Bissantz, C.; Gavelle, O.; Kuratli, C.; Dehmlow, H.; Richter, H. G. F.; Obst Sander, U.; Erickson, S. D.; Kim, K.; Pietranico-Cole, S. L.; Alvarez-Sánchez, R.; Ullmer, C. 2-Phenoxy-Nicotinamides Are Potent Agonists at the Bile Acid Receptor GPBAR1 (TGR5) ChemMedChem 2013, 8 (4) 569-576 10.1002/cmdc.201200474
46. Cox, C. D.; McGaughey, G. B.; Bogusky, M. J.; Whitman, D. B.; Ball, R. G.; Winrow, C. J.; Renger, J. J.; Coleman, P. J. Conformational Analysis of N,N-Disubstituted-1,4-Diazepane Orexin Receptor Antagonists and Implications for Receptor Binding Bioorg. Med. Chem. Lett. 2009, 19 (11) 2997-3001 10.1016/j.bmcl.2009.04.026
47. McGarry, J. D.; Brown, N. F. The Mitochondrial Carnitine Palmitoyltransferase System-From Concept to Molecular Analysis Eur. J. Biochem. 1997, 244 (1) 1-14 10.1111/j.1432-1033.1997.00001.x
48. Stahl, M.; Mauser, H. Database Clustering with a Combination of Fingerprint and Maximum Common Substructure Methods J. Chem. Inf. Model. 2005, 45 (3) 542-548 10.1021/ci050011h
49. Perspicace, S.; Rufer, A. C.; Thoma, R.; Mueller, F.; Hennig, M.; Ceccarelli, S.; Schulz-Gasch, T.; Seelig, J. Isothermal Titration Calorimetry with Micelles: Thermodynamics of Inhibitor Binding to Carnitine Palmitoyltransferase 2 Membrane Protein FEBS Open Bio 2013, 3, 204-211 10.1016/j.fob.2013.04.003
50. Hattori, K.; Wakabayashi, H.; Tamaki, K. Predicting Key Example Compounds in Competitors Patent Applications Using Structural Information Alone J. Chem. Inf. Model. 2008, 48 (1) 135-142 10.1021/ci7002686
51. Tyrchan, C.; Boström, J.; Giordanetto, F.; Winter, J.; Muresan, S. Exploiting Structural Information in Patent Specifications for Key Compound Prediction J. Chem. Inf. Model. 2012, 52 (6) 1480-1489 10.1021/ci3001293
52. Martin, R. E.; Green, L. G.; Guba, W.; Kratochwil, N.; Christ, A. Discovery of the First Nonpeptidic, Small-Molecule, Highly Selective Somatostatin Receptor Subtype 5 Antagonists: A Chemogenomics Approach J. Med. Chem. 2007, 50 (25) 6291-6294 10.1021/jm701143p
53. Reisine, T.; Bell, G. I. Molecular Biology of Somatostatin Receptors Endocr. Rev. 1995, 16 (4) 427-442 10.1210/edrv-16-4-427
54. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Fairlie, D. P. Beta-Strand Mimetics Chem. Rev. 2004, 104 (12) 6085-6118 10.1021/cr040648k
55. Kratochwil, N. A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoener, M. C.; Mühlemann, A.; Porter, R. H. P.; Stahl, M.; Gerber, P. R. An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application J. Chem. Inf. Model. 2005, 45 (5) 1324-1336 10.1021/ci050221u
56. Martin, R. E.; Mohr, P.; Maerki, H. P.; Guba, W.; Kuratli, C.; Gavelle, O.; Binggeli, A.; Bendels, S.; Alvarez-Sánchez, R.; Alker, A.; Polonchuk, L.; Christ, A. D. Benzoxazole Piperidines as Selective and Potent Somatostatin Receptor Subtype 5 Antagonists Bioorg. Med. Chem. Lett. 2009, 19 (21) 6106-6113 10.1016/j.bmcl.2009.09.024
57. Williams, A. J.; Harland, L.; Groth, P.; Pettifer, S.; Chichester, C.; Willighagen, E. L.; Evelo, C. T.; Blomberg, N.; Ecker, G.; Goble, C.; Mons, B. Open PHACTS: Semantic Interoperability for Drug Discovery Drug Discovery Today 2012, 17 (21-22) 1188-1198 10.1016/j.drudis.2012.05.016
58. Bento, A. P.; Gaulton, A.; Hersey, A.; Bellis, L. J.; Chambers, J.; Davies, M.; Kruger, F. A.; Light, Y.; Mak, L.; McGlinchey, S.; Nowotka, M.; Papadatos, G.; Santos, R.; Overington, J. P. The ChEMBL Bioactivity Database: An Update Nucleic Acids Res. 2014, 42 (D1) D1083-D1090 10.1093/nar/gkt1031
59. Mobley, D. L.; Graves, A. P.; Chodera, J. D.; McReynolds, A. C.; Shoichet, B. K.; Dill, K. A. Predicting Absolute Ligand Binding Free Energies to a Simple Model Site J. Mol. Biol. 2007, 371 (4) 1118-1134 10.1016/j.jmb.2007.06.002
60. Chodera, J. D.; Mobley, D. L.; Shirts, M. R.; Dixon, R. W.; Branson, K.; Pande, V. S. Alchemical Free Energy Methods for Drug Discovery: Progress and Challenges Curr. Opin. Struct. Biol. 2011, 21 (2) 150-160 10.1016/j.sbi.2011.01.011
61. Wang, L.; Wu, Y.; Deng, Y.; Kim, B.; Pierce, L.; Krilov, G.; Lupyan, D.; Robinson, S.; Dahlgren, M. K.; Greenwood, J.; Romero, D. L.; Masse, C.; Knight, J. L.; Steinbrecher, T.; Beuming, T.; Damm, W.; Harder, E.; Sherman, W.; Brewer, M.; Wester, R.; Murcko, M.; Frye, L.; Farid, R.; Lin, T.; Mobley, D. L.; Jorgensen, W. L.; Berne, B. J.; Friesner, R. A.; Abel, R. Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field J. Am. Chem. Soc. 2015, 137 (7) 2695-2703 10.1021/ja512751q
62. Durrant, J. D.; McCammon, J. A. Molecular Dynamics Simulations and Drug Discovery BMC Biol. 2011, 9 (1) 71 10.1186/1741-7007-9-71
63. Chen, Y.-C. Beware of Docking! Trends Pharmacol. Sci. 2015, 36 (2) 78-95 10.1016/j.tips.2014.12.001
64. García-Sosa, A. T.; Mancera, R. L.; Dean, P. M. WaterScore: A Novel Method for Distinguishing between Bound and Displaceable Water Molecules in the Crystal Structure of the Binding Site of Protein-Ligand Complexes J. Mol. Model. 2003, 9 (3) 172-182 10.1007/s00894-003-0129-x
65. Young, T.; Abel, R.; Kim, B.; Berne, B. J.; Friesner, R. A. Motifs for Molecular Recognition Exploiting Hydrophobic Enclosure in Protein-ligand Binding Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (3) 808-813 10.1073/pnas.0610202104
66. Truchon, J.-F.; Pettitt, B. M.; Labute, P. A Cavity Corrected 3D-RISM Functional for Accurate Solvation Free Energies J. Chem. Theory Comput. 2014, 10 (3) 934-941 10.1021/ct4009359
67. Amadasi, A.; Surface, J. A.; Spyrakis, F.; Cozzini, P.; Mozzarelli, A.; Kellogg, G. E. Robust Classification of Relevant Water Molecules in Putative Protein Binding Sites J. Med. Chem. 2008, 51 (4) 1063-1067 10.1021/jm701023h
68. Perola, E.; Walters, W. P.; Charifson, P. S. A Detailed Comparison of Current Docking and Scoring Methods on Systems of Pharmaceutical Relevance Proteins: Struct., Funct., Genet. 2004, 56 (2) 235-249 10.1002/prot.20088
69. Plewczynski, D.;Aaźniewski, M.; Augustyniak, R.; Ginalski, K. Can We Trust Docking Results? Evaluation of Seven Commonly Used Programs on PDBbind Database J. Comput. Chem. 2011, 32 (4) 742-755 10.1002/jcc.21643
70. Smith, R. D.; Dunbar, J. B.; Ung, P. M.-U.; Esposito, E. X.; Yang, C.-Y.; Wang, S.; Carlson, H. A. CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions J. Chem. Inf. Model. 2011, 51 (9) 2115-2131 10.1021/ci200269q
71. Smith, R. D.; Damm-Ganamet, K. L.; Dunbar, J. B.; Ahmed, A.; Chinnaswamy, K.; Delproposto, J. E.; Kubish, G. M.; Tinberg, C. E.; Khare, S. D.; Dou, J.; Doyle, L.; Stuckey, J. A.; Baker, D.; Carlson, H. A. CSAR Benchmark Exercise 2013: Evaluation of Results from a Combined Computational Protein Design, Docking, and Scoring/Ranking Challenge. J. Chem. Inf. Model. 2015, 10.1021/acs.jcim.5b00387.
72. Schulz-Gasch, T.; Stahl, M. Scoring Functions for Protein-ligand Interactions: A Critical Perspective Drug Discovery Today: Technol. 2004, 1 (3) 231-239 10.1016/j.ddtec.2004.08.004
73. Hawkins, P. C. D.; Skillman, A. G.; Nicholls, A. Comparison of Shape-Matching and Docking as Virtual Screening Tools J. Med. Chem. 2007, 50 (1) 74-82 10.1021/jm0603365
74. McGaughey, G. B.; Sheridan, R. P.; Bayly, C. I.; Culberson, J. C.; Kreatsoulas, C.; Lindsley, S.; Maiorov, V.; Truchon, J.-F.; Cornell, W. D. Comparison of Topological, Shape, and Docking Methods in Virtual Screening J. Chem. Inf. Model. 2007, 47 (4) 1504-1519 10.1021/ci700052x
75. Stahl, M.; Baier, S. How Many Molecules Does It Take to Tell a Story? Case Studies, Language, and an Epistemic View of Medicinal Chemistry ChemMedChem 2015, 10 (6) 949-956 10.1002/cmdc.201500091